|Bid||51.01 x 800|
|Ask||50.64 x 1000|
|Day's Range||49.81 - 53.55|
|52 Week Range||39.11 - 73.89|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.63|
Emergent Biosolutions Inc (NYSE: EBS ) Tuesday announced a follow-on U.S. government contract for its smallpox vaccine, ACAM2000. There had been widespread investor concern around the delay in this contract, ...
The deal is funded by the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response.
In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years for the continued supply of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS). The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR.
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.
GAITHERSBURG, Md., Aug. 14, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25.00% and 14.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Reaffirms full year 2019 financial forecast and operational goalsProvides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md., Aug. 01, 2019 -- Emergent BioSolutions.
Emergent BioSolutions Inc. (EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile (SNS) over 12 months. This contract option was exercised under the company’s 2016 development and procurement contract with BARDA, valued at up to $1.5 billion, that includes a five-year base period of performance to develop AV7909 for post-exposure prophylaxis of anthrax disease and to deliver an initial three million doses to the SNS, as well as contract options for procurement of up to an additional 50 million doses.
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAITHERSBURG, Md., July 18, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll look at Emergent...
Is Emergent Biosolutions Inc (NYSE:EBS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
Emergent Biosolutions Inc NYSE:EBSView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EBS with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $842 million over the last one-month into ETFs that hold EBS are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
If you're interested in Emergent BioSolutions Inc. (NYSE:EBS), then you might want to consider its beta (a measure of...